These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
242 related articles for article (PubMed ID: 37436162)
1. Vemurafenib Inhibits Acute and Chronic Enterovirus Infection by Affecting Cellular Kinase Phosphatidylinositol 4-Kinase Type IIIβ. Laajala M; Zwaagstra M; Martikainen M; Nekoua MP; Benkahla M; Sane F; Gervais E; Campagnola G; Honkimaa A; Sioofy-Khojine AB; Hyöty H; Ojha R; Bailliot M; Balistreri G; Peersen O; Hober D; Van Kuppeveld F; Marjomäki V Microbiol Spectr; 2023 Aug; 11(4):e0055223. PubMed ID: 37436162 [TBL] [Abstract][Full Text] [Related]
2. ACBD3 Is an Essential Pan-enterovirus Host Factor That Mediates the Interaction between Viral 3A Protein and Cellular Protein PI4KB. Lyoo H; van der Schaar HM; Dorobantu CM; Rabouw HH; Strating JRPM; van Kuppeveld FJM mBio; 2019 Feb; 10(1):. PubMed ID: 30755512 [TBL] [Abstract][Full Text] [Related]
3. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib. Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428 [TBL] [Abstract][Full Text] [Related]
4. Mortalin depletion induces MEK/ERK-dependent and ANT/CypD-mediated death in vemurafenib-resistant B-Raf Wu PK; Hong SK; Park JI Cancer Lett; 2021 Apr; 502():25-33. PubMed ID: 33440231 [TBL] [Abstract][Full Text] [Related]
5. HI-511 overcomes melanoma drug resistance Chang X; Zhang T; Wang Q; Rathore MG; Reddy K; Chen H; Shin SH; Ma WY; Bode AM; Dong Z Theranostics; 2020; 10(21):9721-9740. PubMed ID: 32863956 [No Abstract] [Full Text] [Related]
6. p53 Reactivation by PRIMA-1(Met) (APR-246) sensitises (V600E/K)BRAF melanoma to vemurafenib. Krayem M; Journe F; Wiedig M; Morandini R; Najem A; Salès F; van Kempen LC; Sibille C; Awada A; Marine JC; Ghanem G Eur J Cancer; 2016 Mar; 55():98-110. PubMed ID: 26790143 [TBL] [Abstract][Full Text] [Related]
7. PLX8394, a RAF inhibitor, inhibits enterovirus 71 replication by blocking RAF/MEK/ERK signaling. Wu C; Zhu G; Qiu F; Ren F; Lin B; Zhang D; Yang Q; Huang C Virol Sin; 2023 Apr; 38(2):276-284. PubMed ID: 36669700 [TBL] [Abstract][Full Text] [Related]
8. Novel ATP-competitive MEK inhibitor E6201 is effective against vemurafenib-resistant melanoma harboring the MEK1-C121S mutation in a preclinical model. Narita Y; Okamoto K; Kawada MI; Takase K; Minoshima Y; Kodama K; Iwata M; Miyamoto N; Sawada K Mol Cancer Ther; 2014 Apr; 13(4):823-32. PubMed ID: 24448821 [TBL] [Abstract][Full Text] [Related]
9. Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway. Atefi M; von Euw E; Attar N; Ng C; Chu C; Guo D; Nazarian R; Chmielowski B; Glaspy JA; Comin-Anduix B; Mischel PS; Lo RS; Ribas A PLoS One; 2011; 6(12):e28973. PubMed ID: 22194965 [TBL] [Abstract][Full Text] [Related]
10. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Joseph EW; Pratilas CA; Poulikakos PI; Tadi M; Wang W; Taylor BS; Halilovic E; Persaud Y; Xing F; Viale A; Tsai J; Chapman PB; Bollag G; Solit DB; Rosen N Proc Natl Acad Sci U S A; 2010 Aug; 107(33):14903-8. PubMed ID: 20668238 [TBL] [Abstract][Full Text] [Related]
11. Mitochondrial complex I inhibitor deguelin induces metabolic reprogramming and sensitizes vemurafenib-resistant BRAF Carpenter EL; Chagani S; Nelson D; Cassidy PB; Laws M; Ganguli-Indra G; Indra AK Mol Carcinog; 2019 Sep; 58(9):1680-1690. PubMed ID: 31211467 [TBL] [Abstract][Full Text] [Related]
12. Inhibition of USP14 enhances anti-tumor effect in vemurafenib-resistant melanoma by regulation of Skp2. Wu T; Li C; Zhou C; Niu X; Li G; Zhou Y; Gu X; Cui H Cell Biol Toxicol; 2023 Oct; 39(5):2381-2399. PubMed ID: 35648318 [TBL] [Abstract][Full Text] [Related]
13. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Poulikakos PI; Persaud Y; Janakiraman M; Kong X; Ng C; Moriceau G; Shi H; Atefi M; Titz B; Gabay MT; Salton M; Dahlman KB; Tadi M; Wargo JA; Flaherty KT; Kelley MC; Misteli T; Chapman PB; Sosman JA; Graeber TG; Ribas A; Lo RS; Rosen N; Solit DB Nature; 2011 Nov; 480(7377):387-90. PubMed ID: 22113612 [TBL] [Abstract][Full Text] [Related]
14. Targeting oncogenic Raf protein-serine/threonine kinases in human cancers. Roskoski R Pharmacol Res; 2018 Sep; 135():239-258. PubMed ID: 30118796 [TBL] [Abstract][Full Text] [Related]
15. Protein Kinase CK2α Maintains Extracellular Signal-regulated Kinase (ERK) Activity in a CK2α Kinase-independent Manner to Promote Resistance to Inhibitors of RAF and MEK but Not ERK in BRAF Mutant Melanoma. Zhou B; Ritt DA; Morrison DK; Der CJ; Cox AD J Biol Chem; 2016 Aug; 291(34):17804-15. PubMed ID: 27226552 [TBL] [Abstract][Full Text] [Related]
16. TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanoma. Corcoran RB; Rothenberg SM; Hata AN; Faber AC; Piris A; Nazarian RM; Brown RD; Godfrey JT; Winokur D; Walsh J; Mino-Kenudson M; Maheswaran S; Settleman J; Wargo JA; Flaherty KT; Haber DA; Engelman JA Sci Transl Med; 2013 Jul; 5(196):196ra98. PubMed ID: 23903755 [TBL] [Abstract][Full Text] [Related]
17. Enterovirus 3A Facilitates Viral Replication by Promoting Phosphatidylinositol 4-Kinase IIIβ-ACBD3 Interaction. Xiao X; Lei X; Zhang Z; Ma Y; Qi J; Wu C; Xiao Y; Li L; He B; Wang J J Virol; 2017 Oct; 91(19):. PubMed ID: 28701404 [TBL] [Abstract][Full Text] [Related]
18. Antiviral Peptides Targeting the Helicase Activity of Enterovirus Nonstructural Protein 2C. Fang Y; Wang C; Wang C; Yang R; Bai P; Zhang XY; Kong J; Yin L; Qiu Y; Zhou X J Virol; 2021 May; 95(12):. PubMed ID: 33789997 [TBL] [Abstract][Full Text] [Related]
19. MicroRNA-211 Modulates the DUSP6-ERK5 Signaling Axis to Promote BRAF Lee B; Sahoo A; Sawada J; Marchica J; Sahoo S; Layng FIAL; Finlay D; Mazar J; Joshi P; Komatsu M; Vuori K; de Jong PR; Ray A; Perera RJ J Invest Dermatol; 2021 Feb; 141(2):385-394. PubMed ID: 32888955 [TBL] [Abstract][Full Text] [Related]
20. Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma. Yadav V; Zhang X; Liu J; Estrem S; Li S; Gong XQ; Buchanan S; Henry JR; Starling JJ; Peng SB J Biol Chem; 2012 Aug; 287(33):28087-98. PubMed ID: 22730329 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]